RAMIPRIL TEVA 5 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

RAMIPRIL

متاح من:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

ATC رمز:

C09AA05

الشكل الصيدلاني:

TABLETS

تركيب:

RAMIPRIL 5 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

المجموعة العلاجية:

RAMIPRIL

المجال العلاجي:

RAMIPRIL

الخصائص العلاجية:

- Hypertension - Congestive heart failure - Reduction of mortality in patients after MI with left ventricular dysfunction For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL ( <0.9 mmol/L) current smoker known microalbuminuria clinical evidence of previous vascular disease. - Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

تاريخ الترخيص:

2020-05-31

نشرة المعلومات

דומע
1
ךותמ
4
_ _
_ _
_ :ךיראת_
_ ראוני_
_2018_
_ _ ה/דבכנ ת/חקור ,ה/ אפור
ןולעב םיאבה םינוכדעה תא רשיא תואירבה
דרשמש העידומ עבט תרבח
אפורל/ןכרצל
:רישכתה לש
_ _ עבט לירפימר
5
ג"מ
תוילבט
RAMIPRIL TEVA 5 MG TABLETS
CONTAINS
: :
ליעפה רמוחה תומכו םש
_ _
_PER TABLETS_
_ _
_ _
_RAMIPRIL 5 MG_ ןכרצל ןולעב םינוכדע
------------------------------------------------------------------------------------------------------------
היוותה
יפכ
הרשואש
תדועתב
םושירה :
- Hypertension
- Congestive heart failure
- Reduction of mortality in patients after MI with left ventricular
dysfunction For reducing the risk of
myocardial infarction stoke cardiovascular death or need for
revascularization procedures in patients
over 55 years or more who have clinical evidence of cardiovascular
disease (previous MI unstable
angina or multivessel CABG or multivessel PTCA) stroke or peripheral
vascular disease. Also for
reducing the risk of myocardial infarction stroke cardiovascular death
or need for revascularization
procedures in diabetic patients of 55 years or more who have one or
more of the following clinical
findings : hypertension (systolic blood pressure > 160 mmHg or
diastolic pressure > 90 mmHg) high
total cholesterol (>5.2 mmol/L) low HDL ( <0.9 mmol/L) current smoker
known microalbuminuria
clinical evidence of previous vascular disease.
- Prevention of progressive renal failure in patients with persistent
proteinuria in excess of 1g/day.
ל ןולעהש עידוהל וננוצרב
ןכדוע ןכרצ םיקזוח תרסהו תורמחה םע
2.5
ג"מ
ו
-
10
ןולעהמ ג"מ
הז
. ןלהלש טוריפב תונמוסמ תופסות) דבלב םיירקיעה
םינוכדעה םילולכ
םודאב :(קוחמ טסקטכ עדימ תורסהו
המדקה ליגל תחתמ םירגבתמבו םידליב שומישל
תדעוימ הניא הפורתה
18
1
.
?ה